4006-776-356 出国就医服务电话

免费获得国外相关药品，最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Understanding Chronic Lymphocytic Leukemia

Understanding Chronic Lymphocytic Leukemia

Study Description
Brief Summary:
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.

Condition or disease
Chronic Lymphocytic Leukemia

Detailed Description:
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia, for the potential development of more effective therapies for this disease.
Study Design
Layout table for study information
Study Type : Observational
Estimated Enrollment : 2750 participants
Observational Model: Other
Time Perspective: Other
Official Title: Understanding Chronic Lymphocytic Leukemia
Actual Study Start Date : September 29, 1999
Estimated Primary Completion Date : September 29, 2024
Estimated Study Completion Date : September 29, 2026
Arms and Interventions
Group/Cohort
Sample Collection
  • Blood tests required for assessment
  • Specimens and data will also be collected from outside sites
  • Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute
Outcome Measures
Primary Outcome Measures :
  1. Incidence of novel genomic prognostic markers in Chronic Lymphocytic Leukemia [ Time Frame: 20 years ]
    Exploratory science to better understand Chronic Lymphocytic Leukemia


Biospecimen Retention:   Samples With DNA
peripheral blood mononuclear cells, saliva

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Monoclonal B-cell lymphocytosis or Chronic Lymphocytic Leukemia in any phase of their disease.
Criteria

Inclusion Criteria:

  • New and existing patients seen for treatment of monoclonal B-cell lymphocytosis
  • Any low grade lymphoproliferative disorder
  • Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere

Exclusion Criteria:

-

Contacts and Locations

Contacts
Layout table for location contacts
Contact: Jennifer Brown, MD, PhD 617-582-8437 Jennifer_brown@dfci.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Jennifer Brown, MD, PhD    617-582-8437    Jennifer_brown@dfci.harvard.edu   
Principal Investigator: Jennifer Brown, MD, PhD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Jennifer Brown, MD,PhD Dana-Farber Cancer Institute
Tracking Information
First Submitted Date June 26, 2019
First Posted Date July 22, 2019
Last Update Posted Date July 30, 2020
Actual Study Start Date September 29, 1999
Estimated Primary Completion Date September 29, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 19, 2019) 		Incidence of novel genomic prognostic markers in Chronic Lymphocytic Leukemia [ Time Frame: 20 years ]
Exploratory science to better understand Chronic Lymphocytic Leukemia
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Understanding Chronic Lymphocytic Leukemia
Official Title Understanding Chronic Lymphocytic Leukemia
Brief Summary The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
Detailed Description The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia, for the potential development of more effective therapies for this disease.
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
peripheral blood mononuclear cells, saliva
Sampling Method Non-Probability Sample
Study Population Patients with Monoclonal B-cell lymphocytosis or Chronic Lymphocytic Leukemia in any phase of their disease.
Condition Chronic Lymphocytic Leukemia
Intervention Not Provided
Study Groups/Cohorts Sample Collection
  • Blood tests required for assessment
  • Specimens and data will also be collected from outside sites
  • Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: July 19, 2019) 		2750
Original Estimated Enrollment Same as current
Estimated Study Completion Date September 29, 2026
Estimated Primary Completion Date September 29, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • New and existing patients seen for treatment of monoclonal B-cell lymphocytosis
  • Any low grade lymphoproliferative disorder
  • Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere

Exclusion Criteria:

-
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Jennifer Brown, MD, PhD 617-582-8437 Jennifer_brown@dfci.harvard.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04028531
Other Study ID Numbers 99-224
R01CA213442-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: Boston Childrens Hospital - Contact the Technology & Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu BIDMC - Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu Brigham and Women's Hospital - Contact the Partners Innovations team at http://www.partners.org/innovation Dana Farber Cancer Institute - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu Massachusetts General Hospital - Contact the Partners Innovations team at http://www.partners.org/innovation
Responsible Party Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute
Study Sponsor Dana-Farber Cancer Institute
Collaborators National Cancer Institute (NCI)
Investigators
Principal Investigator: Jennifer Brown, MD,PhD Dana-Farber Cancer Institute
PRS Account Dana-Farber Cancer Institute
Verification Date July 2020

治疗医院

新药特效药

治疗案例

前沿医讯